InflaRx (IFRX) Projected to Release Quarterly Earnings on Thursday

InflaRx (NASDAQ:IFRX) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect InflaRx to announce earnings of ($0.08) per share and revenue of $0.0060 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 7, 2026 at 12:30 PM ET.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. On average, analysts expect InflaRx to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

InflaRx Trading Down 2.4%

Shares of IFRX stock opened at $1.65 on Thursday. The firm’s fifty day moving average price is $2.00 and its two-hundred day moving average price is $1.50. InflaRx has a 1 year low of $0.74 and a 1 year high of $2.95. The firm has a market capitalization of $119.28 million, a P/E ratio of -2.32 and a beta of 2.44.

Analysts Set New Price Targets

Several analysts recently issued reports on IFRX shares. HC Wainwright upped their target price on InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Cantor Fitzgerald upped their price objective on InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Zacks Research raised shares of InflaRx from a “hold” rating to a “strong-buy” rating in a research note on Monday. Wall Street Zen upgraded shares of InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Guggenheim reiterated a “buy” rating and issued a $14.00 price target on shares of InflaRx in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, InflaRx presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in InflaRx during the 4th quarter valued at $135,000. Suvretta Capital Management LLC raised its position in shares of InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after purchasing an additional 1,450,000 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of InflaRx during the 4th quarter worth about $104,000. Squarepoint Ops LLC lifted its stake in shares of InflaRx by 72.0% during the 4th quarter. Squarepoint Ops LLC now owns 324,349 shares of the company’s stock worth $328,000 after buying an additional 135,826 shares during the last quarter. Finally, HRT Financial LP bought a new stake in shares of InflaRx during the 4th quarter worth about $47,000. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.